Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

Key Inclusion Criteria:

• Body weight greater than or equal to (≥)45 kilogram (kg)

• Body mass index (BMI) ≥18 to less than (<) 40 kilogram per meter square (kg/m^2)

• Diagnosis of diabetes mellitus type 1 or type 2 and with glycosylated hemoglobin A1c (HbA1c) ≤9% and the presence of bilateral pain in lower extremities due to DPN forat least 1 year

• Weekly average of daily NPRS score ≥4 and less than or equal to (≤) 9 with limitedvariation in the 7-day Baseline Period

Key Exclusion Criteria:

• More than 3 missing daily NPRS scores during the 7-day Baseline Period

• Received Journavx within 30 days of study drug dosing

• Any sensory abnormality (excluding DPN) as pre-specified in the protocol

Other protocol defined Inclusion/Exclusion criteria may apply.